Somatic mutations in chromatin remodeler genes could modify the epigenomic landscape of CLL, but These are unheard of in this malignancy when compared with other lymphoid neoplasms. CHD2 aberrations and healthy enough to tolerate FCR therapy, may still be excellent candidates to the latter, While